PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+37.7%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.61B
AUM Growth
+$2.61B
(+35%)
Cap. Flow
+$227M
Cap. Flow
% of AUM
8.69%
Top 10 Holdings %
Top 10 Hldgs %
54.25%
Holding
163
New
39
Increased
29
Reduced
17
Closed
28
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$74.4M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$38.7M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$33.8M |
| 4 |
Puma Biotechnology
PBYI
|
$22.8M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$18.9M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$36.7M |
| 2 |
RDUS
Radius Health, Inc.
RDUS
|
$29.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$21.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$13.3M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
$13.3M |
Sector Composition
| 1 | Healthcare | 95.78% |
| 2 | Industrials | 0.33% |
| 3 | Consumer Discretionary | 0.07% |
| 4 | Technology | 0.01% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$13.8B
| $294M | 11.22% | 4,791,589 +1,214,000 | +34% | +$74.4M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $270M | 10.31% | 17,888,597 +591,925 | +3% | +$8.93M |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $210M | 8.03% | 1,788,802 -43,959 | -2% | -$5.16M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $132M | 5.06% | 4,264,066 +330,139 | +8% | +$10.3M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $129M | 4.91% | 3,670,357 +222,055 | +6% | +$7.78M |
|
|
6
Puma Biotechnology
PBYI
$254M
| $111M | 4.23% | 923,820 +190,500 | +26% | +$22.8M |
|
|
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $75M | 2.87% | 2,157,011 | – | – |
|
8
Travere Therapeutics
TVTX
$1.56B
| $66.9M | 2.55% | 2,686,204 +13,895 | +0.5% | +$346K |
|
|
AVXS
9
DELISTED
AveXis, Inc. Common Stock
AVXS
| $64.9M | 2.48% | 671,181 +400,000 | +148% | +$38.7M |
|
|
CORI
10
DELISTED
Corium International, Inc.
CORI
| $64.8M | 2.48% | 5,847,133 | – | – |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $60.3M | 2.3% | 1,616,259 +905,000 | +127% | +$33.8M |
|
|
TSRO
12
DELISTED
TESARO, Inc.
TSRO
| $50.2M | 1.92% | 388,651 +29,100 | +8% | +$3.76M |
|
13
Regenxbio
RGNX
$451M
| $47.5M | 1.81% | 1,441,186 +70,000 | +5% | +$2.31M |
|
|
DOVA
14
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $42.6M | 1.63% | 1,754,015 +47,516 | +3% | +$1.15M |
|
15
Iovance Biotherapeutics
IOVA
$807M
| $36.6M | 1.4% | 4,726,114 +363,000 | +8% | +$2.81M |
|
|
NXTM
16
DELISTED
NxStage Medical Inc.
NXTM
| $34.9M | 1.33% | 1,264,523 -291,000 | -19% | -$8.03M |
|
17
AnaptysBio
ANAB
$569M
| $34.3M | 1.31% | 982,269 +30,000 | +3% | +$1.05M |
|
18
Akebia Therapeutics
AKBA
$833M
| $32.1M | 1.22% | 1,630,000 +530,000 | +48% | +$10.4M |
|
19
Xencor
XNCR
$580M
| $29.6M | 1.13% | 1,293,095 | – | – |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $29.6M | 1.13% | 424,661 -20,000 | -4% | -$1.39M |
|
21
Intuitive Surgical
ISRG
$170B
| $26.4M | 1.01% | 25,195 +4,500 | +22% | +$4.71M |
|
|
VBIV
22
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $25.3M | 0.97% | 6,565,843 | – | – |
|
23
CytomX Therapeutics
CTMX
$336M
| $25.3M | 0.97% | 1,390,381 | – | – |
|
|
DBVT
24
DBV Technologies
DBVT
$264M
| $24.5M | 0.93% | 576,419 -15,346 | -3% | -$651K |
|
25
Humana
HUM
$36.5B
| $24.4M | 0.93% | 100,000 +21,907 | +28% | +$5.34M |
|